Netaccede Enters Inbentus Capital

Inbentus expands its shareholding. The Murcian company specializing in medical technology to develop respirators has given access to its capital to the investment fund of Galician origin Netaccede, as Rafael Valverde, co-founder, and CEO of Inbentus, said. In parallel, the company is preparing the commercial leap for its products by 2024.

Netaccede’s entry into the capital of Inbentus occurs after the company has closed a financing round of €2 million backed, mainly, by BeAble Capital. With the participation of the Galician entity, Inbentus manages to increase its financing, although its exact contribution has not been disclosed.

Netaccede, originally from Vigo, emerged in 2000 as a group-oriented towards the development of new business ideas, becoming a Simplified Regime Venture Capital Company in 2008. Currently, Netaccede is present in construction, telecommunications, strategic consulting and telecommunications, environmental and sanitary, and biosanitary.

Read more about Inbentus and find the most important business news of the day with the Born2Invest mobile app.

Inbentus has raised more than €2 million in private financing

According to the information in the Netaccede information brochure sent to the National Securities Market Commission (Cnmv), on November 30th, 2021, the company’s capital was €2 million, represented by 3.4 million ordinary registered shares with a face value of €0.60 each.

Netaccede, in its capacity as an investment partner, has a vocation of permanence in its investees, generally between three and eight years. Once this period has elapsed, they will agree to divest their participation.

The CEO of Netaccede is Mónica Rodríguez, a Law graduate from the CEU San Pablo University and who was a consultant at Constructnova, as well as having work experience in legal and tax departments.

In 2021, the Murcian company closed its first round of financing with more than €500,000

Inbentus was established during the pandemic with the development of a Covid-19 respirator and has managed to successfully develop the first high-performance medical respirators with turbine technology, being the first in Spain to offer this technology for both intensive care units ( ICU) and for patient transport.

The company hopes to accelerate its growth and expand its research and development capacity for new equipment and technologies related to mechanical ventilation. Likewise, resources will be allocated to the expansion of the company in key international markets.

In 2021, the Murcian company closed its first round of financing with more than €500,000, thanks to the support of Crowdcube and public aid. The founding team of Inbentus, in addition to Valverde, is made up of Juan Andrés Romero, founder of Clerhp Estructuras, a listed Spanish engineering and construction company, and José Ramón García, CEO of La Comarca Food Group. This team holds the majority of the capital.

__

(Featured image by  blickpixel via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.